



Elizabeth A. Hutt
NuGEN Technologies, Inc.
Vice President, Commercial Operations
650.590.3600
ehutt@nugeninc.com

Media contact:
Richard A. Howell
SVM Group for NuGEN
650.346.7425
rhowell@svmgroup.com

NuGEN Granted Patent for RNA Amplification Technology

SAN CARLOS, Calif. – September 20, 2005 – NuGEN Technologies, Inc., a privately held company that develops and commercializes the new standard in nucleic acid amplification and labeling systems, today announced that the United States Patent and Trademark Office issued U.S. Patent No. 6,946,251 entitled "Methods and Compositions for Amplification of RNA Sequences." This patent establishes protection around the company's innovative linear, isothermal RNA amplification technology which has widespread applications in life science research, therapeutic and diagnostics.

The patent covers methods, applications and kits, and provides protection for NuGEN's Ribo-SPIA™ methods and reagents that power NuGEN's Ovation™ family of products. The Ovation™ System provides powerful methods and reagents for both 3' based RNA amplification and whole transcriptome amplification.

The methods enable fast and accurate sample preparation methods for gene expression analysis and profiling from minute samples, and are thus useful for gene expression analysis in precious biological samples. Unlike the commonly used RNA amplification methods that are based on in vitro transcription, Ribo-SPIA™ is a single round amplification that provides very efficient amplification to generate microgram amounts of cDNA products from minute (nanogram level and lower) amounts of total RNA. The simple and fast protocol is easily automatable, enabling high throughput gene expression analysis.

The issue of this U.S. patent strengthens NuGEN's intellectual property portfolio. NuGEN's isothermal nucleic acid amplification technologies are protected by a number of U.S. and foreign issued patents and patent applications.

About NuGEN Technologies Inc.

NuGEN Technologies is focused on the development and commercialization of sensitive, rapid and cost-effective amplification and detection systems for genomic and proteomic research. The company's technologies enable the comprehensive analysis and discovery of biological mechanisms, cellular responses, and disease pathologies. NuGEN's proprietary SPIA™ and Ribo-SPIA™ amplification and labeling system for DNA and RNA based applications, form the foundation for a wide range of methods and products used by life scientists. The Ovation™ amplification and labeling system, the company's first commercially available product line, has applied these technologies to enhancing the sensitivity, convenience, and accuracy of gene expression analysis. Based in San Carlos, CA, NuGEN has a world-class investor syndicate, several collaborations with leading academic and commercial organizations and a management team with significant experience developing and marketing products for research or clinical diagnostic applications.

NuGEN, Ovation, SPIA and Ribo-SPIA are trademarks or service marks of NuGEN Technologies, Inc. All other marks are the property of their respective owners.

This press release contains forward-looking statements that are subject to risks and uncertainties, including continued growth in demand by researchers for total RNA analysis, continued use of oligo and cDNA microarrays, acceptance by researchers of the Company's technologies and products, and competition from existing and newly developed products. Accordingly, actual results may differ materially from those anticipated. These forward-looking statements represent the Company's current expectations as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.

###